文献速递生殖医学妇科

五年研究评估抗癌治疗前抗苗勒管激素检测在育龄期女性癌症患者中的临床效用

Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer.
PubMed 文献 · Reprod Biomed Online · 2019-06-11

前瞻性队列研究纳入66例淋巴瘤和乳腺癌年轻女性,在化疗前、化疗后1年和5年检测血清抗苗勒管激素(AMH),并与124名同年龄范围健康志愿者比较。结果显示癌症患者化疗前AMH已低于健康对照,乳腺癌组基线AMH与5年AMH强相关,5年时月经恢复与基线AMH无显著关联。

要点

  • 育龄期癌症患者化疗前血清AMH已低于同龄健康对照。
  • 乳腺癌患者化疗前AMH与5年卵巢功能显著相关。
  • 化疗后5年月经恢复不能作为卵巢储备的临床指标。

核心结论

  • 育龄期恶性肿瘤女性在开始化疗前血清AMH已低于健康对照。
  • 乳腺癌女性化疗前AMH与长期卵巢功能显著相关。
  • AMH检测可在关键时间点作为年轻癌症女性的生殖健康咨询工具。
  • 研究结果提示月经恢复不适合作为化疗后卵巢储备的临床指标。

研究设计与样本

  • 前瞻性队列研究,纳入66例淋巴瘤和乳腺癌年轻女性,在化疗前及化疗后1年、5年检测血清AMH,并与124名同年龄范围(18-43岁)健康志愿者比较。
  • 随访5年期间同步记录患者月经和活产情况。

主要发现

  • 年龄校正后,健康志愿者化疗前血清AMH为癌症患者的1.4倍(95%CI 1.1至1.9;P<0.02)。
  • 乳腺癌组基线AMH与5年AMH强相关(P<0.001,回归系数=0.58,95%CI 0.29至0.89)。
  • 5年时是否存在月经与基线血清AMH之间无显著关联(逻辑回归似然比检验)。

临床怎么用

  • 作者认为AMH检测可在关键时间点作为年轻癌症女性的生殖健康咨询工具。
  • 作者指出月经恢复不适合作为化疗后卵巢储备的临床指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: An important discussion point before chemotherapy is ovarian toxicity, a side-effect that profoundly affects young women with cancer. Their quality of life after successful treatment, including the ability to conceive, is a major concern. We asked whether serum anti-Müllerian hormone (AMH) measurements before chemotherapy for two most common malignancies are predictive of long-term changes in ovarian reserve? DESIGN: A prospective cohort study measured serum AMH in 66 young women with lymphoma and breast cancer, before and at 1 year and 5 years after chemotherapy, compared with 124 healthy volunteers of the same age range (18-43 years). Contemporaneously, patients reported their menses and live births during 5-year follow-up. RESULTS: After adjustment for age, serum AMH was 1.4 times higher (95% CI 1.1 to 1.9; P < 0.02) in healthy volunteers than in cancer patients before chemotherapy. A strong correlation was observed between baseline and 5-year AMH in the breast cancer group (P < 0.001, regression coefficient = 0.58, 95% CI 0.29 to 0.89). No significant association was found between presence of menses at 5 years and serum AMH at baseline (likelihood ratio test from logistics regression analysis). CONCLUSIONS: Reproductive-age women with malignancy have lower serum AMH than healthy controls even before starting chemotherapy. Pre-chemotherapy AMH was significantly associated with long-term ovarian function in women with breast cancer. At key time points, AMH measurements could be used as a reproductive health advisory tool for young women with cancer. Our results highlight the unsuitability of return of menstruation as a clinical indicator of ovarian reserve after chemotherapy.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Palinska-Rudzka KE, Ghobara T, Parsons N, et al. Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer. Reprod Biomed Online. 2019. PMID: 31471141. doi:10.1016/j.rbmo.2019.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。